Join to View Full Profile
950 Ryland StReno, NV 89502
Phone+1 775-329-0286
Fax+1 775-329-4243
Dr. Khanani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Texas Tech University Health Sciences Center at LubbockResidency, Ophthalmology, 2005 - 2008
Baylor College of MedicineInternship, Internal Medicine, 2004 - 2005- Texas Tech University Health Sciences Center School of MedicineClass of 2004
Certifications & Licensure
NV State Medical License 2010 - 2027
TX State Medical License 2007 - 2012
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
- A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA Start of enrollment: 2014 Aug 01
- Cooling Anesthesia for Intravitreal Injection Start of enrollment: 2018 Nov 30
Publications & Presentations
PubMed
- Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial.Arshad M Khanani, Carl J Danzig, Jeffrey S Heier, Glenn J Jaffe, Peter K Kaiser
Ophthalmology. 2025-12-15 - Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment.Arshad M Khanani, Sophie J Bakri, Carl Regillo, Christina Y Weng, Tien Y Wong
Eye. 2025-12-01 - Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis.Ceren Soylu, Giulia Corradetti, Mai Alhelaly, Hannah Khan, Aamir A Aziz
American Journal of Ophthalmology. 2025-12-01
Journal Articles
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationArshad M Khanani, Sunil S Patel, Philip J Ferrone, Pravin U Dugel, JAMA Ophthalmology
Authored Content
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Press Mentions
Astellas Announces New Data Demonstrating Long-Term Efficacy of Izervay in Slowing GA ProgressionOctober 20th, 2025- Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025October 14th, 2025
- Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical AdvisorsAugust 25th, 2025
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
